Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Philippe Moreau, Brian G.M. Durie et al.|Journal of Clinical Oncology|2015Cited by 2.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myelomaNiccolò Bolli, Nikhil C. Munshi, Hervé Avet‐Loiseau et al.|Nature Communications|2014Cited by 906
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentCatherine Roche‐Lestienne, Claude Preudhomme, Valérie Soenen et al.|Blood|2002Cited by 517
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Albert Oriol et al.|The Lancet Oncology|2019Cited by 383
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Simon J. Harrison, Asher Chanan‐Khan et al.|Blood|2017Cited by 271